

# A Nano-Platform for in situ Investigations of Ovarian Follicles

Jean M. Feugang (✉ [j.feugang@msstate.edu](mailto:j.feugang@msstate.edu))

Mississippi State University <https://orcid.org/0000-0002-1376-5059>

**Ghassan Ishak**

Southern Illinois University Carbondale

**Matthew Eggert**

Auburn University

**Robert Arnold**

Auburn University

**Scott Willard**

Mississippi State University

**Peter Ryan**

Mississippi State University

**Eduardo Gastal**

Southern Illinois University Carbondale

---

## Research

**Keywords:** Liposome vesicles, Molecular imaging, Nanoparticles, Targeted drug delivery, Ovarian follicles, Intrafollicular injection, Livestock, Assisted reproductive technology

**Posted Date:** September 22nd, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-78063/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 **A nano-platform for *in situ* investigations of ovarian follicles**

2

3 J M Feugang<sup>1,\*</sup>, G M Ishak<sup>2,3</sup>, M Eggert<sup>4</sup>, R D Arnold<sup>4</sup>, S T Willard<sup>1</sup>, P L Ryan<sup>1</sup>, E L Gastal<sup>3</sup>

4

5 <sup>1</sup> *Department of Animal and Dairy Sciences, Mississippi State University, Mississippi State, MS,*

6 *USA*

7 <sup>2</sup> *Department of Surgery and Obstetrics, College of Veterinary Medicine, University of Baghdad,*

8 *Baghdad, Iraq*

9 <sup>3</sup> *Department of Animal Science, Food and Nutrition, Southern Illinois University, Carbondale,*

10 *Illinois, USA*

11 <sup>4</sup> *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn*

12 *University, Auburn, AL, USA*

13

14

15 \* **Corresponding author:** Jean M. Feugang, Department of Animal and Dairy Sciences,

16 Mississippi State University, Mississippi State, MS, USA. 335 Wise Center, PO Box 9815

17 Mississippi State, MS 39762. Tel. (662) 325-7567; FAX: (662) 325-8873 E-mail:

18 [j.feugang@msstate.edu](mailto:j.feugang@msstate.edu)

19

20

## 21 **Abstract**

22 **Background:** Despite the growing array of assisted reproductive techniques, there is still a lack  
23 of rapid, non-cytotoxic, and minimally invasive *in situ* approaches for further enhancements  
24 through cell targeting. Here we synthesized clinically relevant liposome nanoparticles for real-  
25 time cellular targeting and drug (doxorubicin) delivery, using pigs and mares as animal models.  
26 In Experiment 1, fluorescently labeled and doxorubicin-loaded (without fluorescent probe)  
27 liposomes were injected in cultured pig ovarian follicles to assess plasma membrane binding and  
28 intracellular doxorubicin delivery. In Experiment 2, fluorescent liposomes were *in vivo* injected  
29 into small and large ovarian follicles of living mares to assess their binding capability to  
30 follicular cells. Twenty-four hours post-injection, all cultured pig follicles were collected while  
31 mare samples (i.e., follicle wall fragments, granulosa cells and follicular fluids) were harvested  
32 through follicle wall biopsy (FWB), and follicle aspiration and flushing techniques using  
33 transvaginal ultrasound-guided approach.

34 **Results:** All injected follicles were healthy and samples were subjected to fluorescence imaging  
35 before and after fixation. Findings revealed successful intrafollicular migration and binding of  
36 liposomes to all follicle cell layers (granulosa, theca interna, and theca externa) regardless of the  
37 follicle size. The intracellular delivery of doxorubicin was confirmed with the staining of nuclei  
38 of follicle cells.

39 **Conclusions:** This study demonstrates the promising combination of the FWB technique and  
40 nanotechnology tools for real-time monitoring of intrafollicular treatment, follicular health and  
41 oocyte development, which in turn has the potential to help understand the mechanisms of  
42 ovulatory dysfunction and to select high-quality oocytes for assisted reproduction techniques.

43

44 **Keywords:** Liposome vesicles, Molecular imaging, Nanoparticles, Targeted drug delivery,  
45 Ovarian follicles, Intrafollicular injection, Livestock, Assisted reproductive technology

46

## 47 **Background**

48 The current efforts to overcome fertility problems through assisted reproductive technologies  
49 (ARTs) are still unsatisfactory because of the insufficient maturation of the oocytes and/or the  
50 existing follicular diseases [1-6]. Furthermore, the ability to assess the quality of the oocytes  
51 mainly, if not only, through *in vitro* manipulations constitutes a serious limitation [7, 8]. Hence,  
52 the development of novel methods for *in situ* assessment of oocyte quality and local (versus  
53 systemic) treatments of unhealthy follicles prior to the retrieval of enclosed oocytes would be of  
54 great interest.

55 Challenges related to female fertility treatments need the investigation of various  
56 methodologies. For example, the routine systemic drug injections (i.e., exogenous  
57 gonadotropins) for controlled ovarian hyperstimulation (COH) is showing increased evidence of  
58 detrimental effects on oogenesis, embryo quality, and endometrial receptivity [9-12]. Hence,  
59 intrafollicular injection, which has been applied in large animals (e.g., cow and mare) with  
60 relative success [4, 13], may become a viable alternative to COH, and the recent advances in  
61 nanotechnology and assisted reproduction tools are likely to boost the outcomes of intrafollicular  
62 treatments.

63 At present, the primary use of “naked” biomolecules, without a carrier, for intrafollicular  
64 injection has drastically limited their potential to gain mechanistic insights related to follicle

65 growth and oocyte maturation. Interestingly, the recent detection of extracellular membrane  
66 microvesicles in equine [14], human [15], and bovine [16] follicular fluid (FF) and their roles as  
67 delivery carriers of biomolecules (e.g., lipids, proteins, RNAs, and miRNA) enabling  
68 intercellular communications have prompted new interest in the use of liposome nanoparticles  
69 for intrafollicular injections [17-19]. Liposomes are clinically relevant carbon-based  
70 nanoparticles shaped like spherical vesicles constituted of phospholipid bilayers providing  
71 biocompatibility, biodegradability, and low toxicity to cells [20]. These nanoparticles have been  
72 used as effective carriers for controlled and rapid deliveries of various hydrophilic and  
73 hydrophobic molecules to specific biological sites, with indubitable benefits during *in vivo* and *in*  
74 *vitro* applications [21, 22]. For fertility treatments, several drugs, including biomolecules that are  
75 found in the FF [23-27], can be loaded into liposomes for intrafollicular injections.

76 Following intrafollicular injections, the minimally invasive *in vivo* Follicle Wall Biopsy  
77 (FWB) technique is a recently improved methodology for assisted reproduction allowing for  
78 simultaneous sampling of the follicle environment (FF, granulosa, theca interna and externa  
79 cells) for *ex vivo* examinations. Most importantly, the FWB technique is performed on living  
80 mares without affecting their fertility, ovarian function, or the FF composition, therefore  
81 providing an excellent cocktail for biomarkers research and clinical purposes [28, 29]. Its  
82 combination with the encapsulated liposomes for intrafollicular deliveries can be highly effective  
83 for a more in-depth understanding of the molecular mechanisms governing follicle growth and  
84 oocyte maturation.

85 In the current study, fluorescent and non-fluorescent unilamellar liposome vesicle  
86 nanoparticles were synthesized. Fluorescence was used for the visualization of the tissular

87 distribution, and non-fluorescent liposomes were loaded with doxorubicin to assess intercellular  
88 delivery. The effectiveness of the liposome nanoparticles in binding the plasma membrane of  
89 follicle cells and delivering doxorubicin was tested *in vitro* with cultured pig ovarian follicles (*ex*  
90 *situ* - *Experiment 1*). Thereafter, as the first step to implement *in situ* fertility treatments and  
91 deep-tissue imaging, the binding capability of liposomes in living animals was tested using intact  
92 equine ovarian follicles (*in situ* – *Experiment 2*).

93

## 94 **Results**

### 95 **Characterization of synthesized liposome nanoparticles**

96 The formulated liposome characterization in Tris buffer pH 7.5 indicated a z-average  
97 nanoparticle diameter of 124.7 nm (PDI = 0.106), a number average diameter of  $87.7 \pm 27.5$  nm  
98 (Fig. 1A), and a zeta potential mean of  $-22.9 \pm 9.51$  mV (Fig. 1B). The addition of 1% DiI to the  
99 formulated fluorescent liposomes led to a final hydrodynamic average diameter of  $109.9 \pm 17.5$   
100 nm, while the TEM imaging indicated a dry average diameter of  $21.3 \pm 4.5$  nm ( $\pm$  SEM),  
101 calculated for thirty random liposomes (Fig. 1A- Insert). For this study, three independent  
102 liposomes were formulated with high fluorescence intensity ( $1.9 \times 10^{11} \pm 8. \times 10^9$  radiance; Fig.  
103 2A). Their mixture and dilution with PBS resulted in the working liposome solution of  $23.1 \mu\text{M}$   
104 DiI dye with fluorescence intensity of  $6.5 \times 10^{10}$  radiance (IVIS imaging; Fig. 2B).

105

### 106 **Experiment 1. Assessment of liposome binding and doxorubicin delivery in cultured** 107 **porcine follicles**

#### 108 **IVIS imaging of dissected porcine antral follicles**

109 Decreasing fluorescence signals with PBS-injected liposomes (auto fluorescence; upper follicle  
110 series) when compared to those injected with fluorescence liposomes (middle follicle series) or  
111 liposomal encapsulated doxorubicin (lower follicle series) can be seen in Figure 3A. Data  
112 quantification confirmed higher ( $P < 0.05$ ) fluorescence signals of both liposome- ( $1.35 \times 10^9 \pm$   
113  $5.31 \times 10^8$ ) and doxorubicin-injected follicles ( $1.82 \times 10^9 \pm 8.38 \times 10^8$ ) and radiant efficiency,  
114 when compared with the PBS-injected group ( $3.93 \times 10^8 \pm 1.53 \times 10^8$ ; Figure 3B); however, the  
115 fluorescence signals in both liposome and doxorubicin groups were comparable ( $P > 0.05$ ).

116

### 117 **Microscopy imaging of liposome binding and doxorubicin delivery**

118 Imaging was performed on follicle wall sections on microscope slides. Autofluorescence or  
119 low/background fluorescence can be observed in sections of follicles injected with PBS (Fig.  
120 4A). In contrast, the highest fluorescence intensity observed in the plasma membranes of follicle  
121 wall cells confirmed the liposome binding (Fig. 4B). The successful binding of doxorubicin-  
122 loaded liposomes to cellular plasma membranes and the delivery of doxorubicin ( $10 \mu\text{g}/\text{follicle}$ )  
123 to the nucleus (red dots) of various cell types of the follicle wall (Fig. 4C) were observed; and  
124 highlights the colocalization of red (doxorubicin) and blue staining (DAPI) within the nuclei can  
125 be seen in Figure 4D- Insert.

126

### 127 **Experiment 2. *In vivo* liposome binding in living mares and *ex vivo* imaging**

128 A total of 22 growing and healthy follicles of nine mares (2-3 follicles/mare) were successfully  
129 injected with  $130 \mu\text{l}$  of fluorescent liposomes working stock solution.

130

### 131 **IVIS imaging of FWB**

132 All FWB samples were of comparable areas ( $3.5 \pm 0.3 \text{ mm}^2$ ), and those of liposome-injected  
133 follicles exhibited fluorescence intensities above background (Control;  $6.7 \times 10^8 \pm 1.44 \times 10^7$   
134 radiant efficiency; Fig. 5A). The FWB derived from both small and large follicles had  
135 comparable fluorescence intensities ( $1.74 \times 10^9 \pm 7.6 \times 10^8$  and  $1.98 \times 10^9 \pm 3.4 \times 10^8$  radiant  
136 efficiency, respectively,  $P > 0.05$ ; Fig. 5B). *In vitro* labeling of FWB with an equivalent amount  
137 of liposomes ( $130 \mu\text{l} = 1.2 \text{ nmoles}$ ; 60 min at  $37^\circ\text{C}$ ) led to higher ( $3.92 \times 10^9 \pm 1.11 \times 10^8$  radiant  
138 efficiency,  $P < 10^{-4}$ ) fluorescence intensity than that of other groups (Fig. 5B).

139

### 140 **IVIS imaging of intrafollicular fluid**

141 The FF of both non-injected (control) and PBS-injected follicles emitted low fluorescence  
142 intensities that were considered background and subtracted from those of FF harvested from  
143 small (Fig. 6A) and large (Fig. 6B) follicles injected with liposomes ( $P < 10^{-4}$ ; Fig. 6C). Data  
144 quantification shows higher fluorescence intensity from small follicles' FF ( $2.95 \times 10^9 \pm 9.65$   
145  $\times 10^8$  radiant efficiency) than their large counterparts ( $8.53 \times 10^8 \pm 0.98 \times 10^8$  radiant efficiency).

146

### 147 **IVIS imaging of granulosa cells (GC)**

148 Fluorescence signals of GC harvested from both small and large follicles were above background  
149 (non-injected or control follicles:  $7.4 \times 10^8 \pm 1.23 \times 10^7$  radiant efficiency,  $P < 10^{-5}$ ; Fig. 7A).  
150 Large follicles' GC produced higher fluorescence than that of small follicles ( $1.61 \times 10^9 \pm 6.83$   
151  $\times 10^7$  vs.  $9.12 \times 10^8 \pm 1.67 \times 10^7$  radiant efficiency,  $P < 0.05$ ; Fig. 7B).

152

### 153 **Confocal microscope fluorescence imaging of FWB samples and flushed granulosa cells**

154 The uniform staining of cell nuclei with DAPI (blue) revealed the good health status of harvested  
155 samples. Follicles injected with PBS did not show any fluorescence (green staining)  
156 corresponding to the presence of liposomes (Fig. 8A). In contrast, follicles injected with  
157 liposomes displayed green fluorescence staining within the plasma membrane of the follicle wall  
158 cells (Fig. 8B). The insert in Figure 8B highlights the fluorescence signal on the plasma  
159 membrane surrounding the blue staining of the nuclei; this observation is confirmed with the  
160 images of flushed mural granulosa cells showing stronger fluorescence signals within the plasma  
161 membrane (Fig. 8C,D). The smeared fluorescence signals seen in Figure 8C,D on the tissues  
162 surrounding the GC correspond to liposomes bound/trapped within the extracellular matrix.

163

### 164 **Discussion**

165 Many factors, such as the physiological conditions of animals and the available technologies, are  
166 prone to influence assisted reproduction outcomes in animals. Here we examined a clinically  
167 relevant liposome vesicle nanoparticle as a potentially powerful, non-invasive diagnostic and  
168 therapeutic agent for future assessment and treatment of ovarian follicles prior to oocyte  
169 recovery. Monovular (mare) and polyovular (pig) species were used to demonstrate the likely  
170 application of our proposed technological approach for *in situ* follicle investigation and  
171 improvement of female fertility.

172 Herein, the sizes of the synthesized liposomes were comparable to those in previous reports  
173 [20, 30, 31], while the injected volumes (5  $\mu$ l in pigs and 200  $\mu$ l in mares) and incubation time  
174 (24 h) were lesser or equal to those reported in previous studies [4, 32]. Hence, the absence of

175 morphological changes in both equine and porcine ovarian follicles' structures following  
176 intrafollicular injections was highly important, with the prospect of performing local deliveries  
177 (i.e., intrauterine or intrafollicular) of molecules at minimal effective doses to reach the targeted  
178 cells during ovarian follicle treatments [33]. These minimal effective doses following local  
179 injections (*vs.* systemic treatments) were demonstrated in mares [34] and cows [13] using  $\text{PGF2}\alpha$   
180 ( $\leq 0.1$  mg *vs.* up to 50-fold greater) and hCG (1.0 IU *vs.* up to 1000-fold greater), respectively.  
181 The ability to by-pass the systemic route (i.e., intramuscular or intravenous) and avoid the  
182 dilution with the blood-stream through local injections of growing antral follicles permits the  
183 study of the direct effects of biocompounds (insulin-like growth factor 1, eCG, and  $\text{PGF2}\alpha$ )  
184 during folliculogenesis [4, 34, 35]. These studies highlight the promising interest in  
185 intrafollicular treatments in animal production and veterinary medicine; however, most related  
186 studies use “naked” (devoid of additional carriers) biomolecules whose ability to cross cell  
187 membranes and short lifespan may be jeopardized during long incubations or journeys.

188 Interestingly, the current progress in nanotechnology is increasing the popularity of  
189 nanoparticles in biomedicine. These nanoparticles possess specific properties (e.g., size-  
190 dependent synthesis, bright and broad-spectrum fluorescence, biocompatibility and  
191 bioconjugation capability) that can be exploited for further investigation and improvement of  
192 reproductive outcomes [22, 32, 36]. In the present study, we used liposomes shaped like  
193 extracellular membrane microvesicles (EVs), which are nano- and micro-size vesicles naturally  
194 released from cells to mediate a new type of cell-to-cell communication through passive  
195 interactions [17, 18, 37]. Likewise, liposomes can interact and fuse with somatic cells (e.g.,  
196 MCF-7 breast cancer cells) within approximately five minutes post-incubation [38]. In the

197 present study, the pig model allowed the (IVIS) imaging of the full and intact follicle, indicating  
198 the possibility for *in situ* non-invasive monitoring of folliculogenesis through molecular imaging  
199 of key biological processes. With the existing fluorescence spectrum of hydrophobic dyes, it is  
200 reasonable to anticipate the formulation of specific labeled liposomes for multiplex molecular  
201 imaging for real-time examinations of various follicular phenomena related to aging, ovarian  
202 cyclicity (cycling *vs.* anestrous phase), structural variations (antral follicles *vs.* corpus luteum),  
203 reproductive phases (estrous *vs.* diestrous), and health (follicle diseases). Understanding of them  
204 may have beneficial implications for women, who are known to share many reproductive  
205 similarities with mares [39].

206 The present study highlights the advantage of combining nanotechnology with granulosa cell  
207 aspiration and *in vivo* FWB techniques to provide more insights into the intrafollicular  
208 microenvironment. Recently, the FWB technique was validated for simultaneous collections of  
209 follicle wall fragments and FF samples from the same living mare [28, 29]. Here, we first  
210 observed that the expected unidirectionality of liposome binding, from the follicular antrum to  
211 the theca externa, leading to lower fluorescence intensity of *in situ* labeled biopsies contrasted  
212 with the likely multidirectional binding during *ex situ* labeling; consequently, all follicle cell  
213 types simultaneously interacted with the liposomes *ex situ* to generate stronger fluorescence  
214 signals. Second, the higher fluorescence of FFs in small follicles was indicative of the low  
215 abundance of cells capable of uptaking liposomes. And third, the high abundance of cells in large  
216 follicles permitted the binding of more liposomes, leading to reduced unbound fluorescent  
217 liposomes in the corresponding FFs. Nonetheless, fluorescence intensity variations between

218 samples certainly corresponded to the possible losses of liposomes during injections, while the  
219 higher fluorescence of large follicles' granulosa cells was attributed to their greater density.

220 The random and passive characteristics of injected liposomes to fuse with follicular cells'  
221 membranes makes them suitable for intracellular deliveries. Indeed, liposomes are among the  
222 numerous carriers with efficient intracellular delivery of cargo of molecules such as proteins,  
223 nucleic acids, metabolites, and even drugs [14, 17, 18, 36, 38]. Our findings revealed the  
224 effective internalization of doxorubicin with its binding to the cell nucleus of all follicle cell  
225 types, demonstrating the far-reaching capacity of the proposed injection route.

226

## 227 **Conclusions**

228 The current study demonstrates 1) the combination of FWB technique and nanotechnology tools  
229 as a promising approach for potential local treatments of ovarian follicle diseases and  
230 enhancement of reproductive performance; 2) the possibility for deep-tissue (plain or targeted)  
231 imaging using fluorescent-labeled liposomes for *in situ* tracking of molecular and/or cellular  
232 processes throughout the antral follicle growth; and 3) the possible use of a formulated liposome  
233 carrier in both mono- and polyovulator animals as well as in living large animals. We believe the  
234 proposed methodology is likely to support future intrafollicular attempts to promote follicle  
235 and/or oocyte growth and to develop treatments to address follicle diseases such as luteinized  
236 unruptured follicle in mares and, potentially, in women as well [5, 40].

237

## 238 **Methods**

### 239 **Chemical and reagents**

240 Phospholipid, DPPC (1, 2-dipalmitoyl-sn-glycero-3-phosphocholine) was purchased from Avanti  
241 Polar Lipids, Inc. (Alabaster, Alabama, USA). Ultrapure grade cholesterol was obtained from  
242 Amresco, Inc. (Solon, Ohio, USA). Lipophilic probes, 1, 1'-dioctadecyl-3, 3', 3'-  
243 tetramethylindocarbocyanine perchlorate (DiIC18(3) or DiI) and 3,3'-  
244 dioctadecyloxycarbocyanine perchlorate (DiOC18(3) or DiO), were acquired from Biotium, Inc.  
245 (Hayward, California, USA). Any additional reagents, chemicals, or solvents of necessary  
246 molecular biology or analytical grade were obtained through commercial sources.

247

## 248 **Liposome nanoparticle preparation and characterization**

249 ***Fluorescence liposome formulation.*** Pegylated liposomes were prepared as previously described  
250 [41, 42]. Briefly, formulations were generated according to a ratio of 10  $\mu\text{mol}$  DPPC, 5  $\mu\text{mol}$   
251 cholesterol, and 100 nmol of the fluorescent lipophilic probe, DiI (~1 mol % of lipid membrane),  
252 per milliliter of dispersant. The lipids and probe, dissolved in chloroform, were mixed and then  
253 dried under a rotary vacuum via a Buchi Rotavapor r-200 (Postfach, Switzerland) to create a  
254 thin film. Subsequently, films were hydrated in an isotonic solution of either 10% (w/v) sucrose  
255 or phosphate-buffered saline to yield 10  $\mu\text{mol}$  phospholipid/mL. Liposomes underwent seven  
256 freeze/thaw cycles via liquid nitrogen and a 60°C water-bath above lipid phase transition  
257 temperature as a means to eliminate additional membrane layers. Formulations were then  
258 extruded using a Lipex extruder (Northern Lipids Inc., Burnaby, British Columbia, Canada)  
259 under high pressure through double-stacked laser etched polycarbonate 80 nm filters (GE  
260 Osmonics, Trevose, Pennsylvania, USA) at heated conditions again above DPPC's phase  
261 transition temperature ( $T_c = 41^\circ\text{C}$ ) for seven times before stabilizing the lipid membranes using

262 an ice-bath for 10 min. Afterward, the liposome dispersions were dialyzed with a 12–14 kDa  
263 SpectraPor Dialysis membranes against fresh isotonic solution as used in hydration for a period  
264 of 1, 4, and 16 hours at 4°C to remove any non-membrane associated probe. Liposomes were  
265 sterilized by terminal filtration (0.22 µm filter) and stored in a sterile glass container under  
266 nitrogen atmosphere at 4°C, protected from light, and used within 3 weeks of preparation. Lipid  
267 concentration was determined for all formulations using an inorganic phosphate assay [43].  
268 Thereafter, the dispersion was diluted to 10 µmol/ml (10 mM), and average stock solutions of  
269 liposome nanoparticles ( $9.24 \pm 0.72$  µmol/ml or 9.24 mM) were constituted and stored at 4°C for  
270 experiments. The DiI lipophilic probe fluoresced at 570 nm following a 480 nm wavelength  
271 excitation.

272

273 ***Doxorubicin-loaded liposome formulation.*** A nonfluorescent pegylated liposomal was  
274 formulated by Avanti Polar Lipids, Inc. (Alabaster, Alabama, USA) and used to encapsulate the  
275 naturally fluorescing doxorubicin (Dox-NP; referenced maxima Ex/Em of 480nm/590nm). All  
276 samples were stored at 4°C for experiments.

277

278 ***High-Resolution Transmission Electron Microscopy and Fluorescence imaging.*** A subset of  
279 synthesized liposomes was visualized under a high-resolution transmission electron microscope  
280 (HR-TEM-2100, 200 kV) with Gatan Orius 832 camera (JEOL; Peabody, Massachusetts, USA),  
281 while another subset was subjected to non-invasive and real-time fluorescence imaging using the  
282 In Vivo Imaging System 200, Lumina XRMS Series III system (IVIS; PerkinElmer; Waltham,  
283 Massachusetts, USA).

284

**285 Experiment 1. Porcine antral follicle culture and intrafollicular liposome injection**

286 Porcine ovaries were harvested in a pre-warmed 0.9% NaCl solution at a local slaughterhouse  
287 and transported immediately to the laboratory. Visible and morphologically normal antral  
288 follicles (4–8 mm in diameter) were dissected and randomly distributed in a set of 24-well tissue  
289 culture plates (3–4 follicles/well); subsequently, the tissue culture plates were placed in a 5%  
290 CO<sub>2</sub> incubator as previously reported [32]. After 24 h of culture at 37°C in a humidified  
291 environment, follicles were microinjected using FemtoJet microinjection system (Eppendorf;  
292 Hauppauge, New York, USA) with 5 µl of Phosphate-Buffered Saline solution (PBS) or 46 nmol  
293 of fluorescent liposomes. Thereafter, injected follicles were returned to their respective culture  
294 wells with half of the medium renewed (1.5 ml of NCSU-23 based medium) and re-incubated for  
295 an additional day of culture. A subset of non-injected follicles was kept in culture to serve as  
296 controls for auto-fluorescence. Following culture, follicles were carefully removed from culture  
297 wells and washed twice in PBS solution prior to non-invasive IVIS fluorescence imaging.  
298 Thereafter, follicles were processed for standard histology and fluorescence microscopic  
299 imaging.

300

**301 Experiment 2. *In vivo* liposome binding tests in living mares****302 *Animals, ultrasonography examination, and intrafollicular fluorescent liposome injection.***

303 Nine nonlactating and cycling Quarter Horse breed mares, 8–14 years old, and weighing  
304 400–600 Kg were used during the ovulatory season. Mares were kept under natural light in  
305 pasture and were maintained with free access to water and trace-mineralized salt. Ovarian follicle

306 tracking was performed daily starting on day 10 of the estrous cycle (day 0 = ovulation) until  
307 follicles reached the designated diameter. Ultrasonographic follicle tracking was carried out  
308 using a duplex color Doppler ultrasound machine (Aloka SSD-3500; Hitachi Aloka Medical  
309 America, Inc., Wallingford, CT, USA) equipped with a finger-mounted 3.5–10 MHz convex-  
310 array transducer (UST-995-7.5). After identification and mapping of small (15–23 mm; n = 12)  
311 and large (24–30 mm; n = 10) follicles that showed continuous growth for a minimum of three  
312 consecutive days, fluorescent liposome nanoparticles (130  $\mu$ l; 23.1  $\mu$ M or 1.2 nmol) were  
313 injected into each growing follicle using a double-channel injection system as previously  
314 described [4, 44]. All mares (n = 9) were used for the injection of 22 follicles (12 small and 10  
315 large), corresponding to 2–3 follicles per mare. One small and one large noninjected follicle  
316 served as experimental controls. After follicle injections, all mares were released to the pasture  
317 for 24 h. Thereafter, all samples (FWB, FF, and isolated granulosa cells) were collected for  
318 analyses.

319  
320 ***Mare antral follicle wall biopsy and follicular fluid collection.*** A novel FWB technique recently  
321 developed in our lab [29] was used to simultaneously harvest FWB and FF from PBS- and  
322 liposome-injected follicles (7 small and 7 large) and one non-injected (control) follicle. This  
323 technique uses an endoscopic biopsy forceps (5 FR gauge, 60 cm, Karl Storz, Berlin, Germany)  
324 located inside a 12 G needle/cannula and mounted on a 5–10 MHz transvaginal ultrasound-  
325 guided convex array transducer (Aloka UST-987-7.5). The FWB samples measured  
326 approximately  $3.5 \pm 0.3$  mm<sup>2</sup> in area, as previously reported [29]. Immediately after FWB  
327 harvesting, FF was collected while the needle was still inside the follicle. Intrafollicular fluid

328 samples were centrifuged at 4°C (1,500 g for 10 min), and the supernatant of each FF sample  
329 was stored in light safe black Eppendorf tubes at 4°C.

330

331 ***In situ collection of equine granulosa cells.*** The remaining injected (6 small and 5 large) and  
332 non-injected (1) follicles were flushed with 120–150 ml of pre-warmed (38°C) Vigro complete  
333 embryo flush with BSA solution (Bioniche; Pullman, WA, USA) containing 2 IU/ml heparin  
334 (H3149, Sigma-Aldrich; Saint-Louis, MO, USA), and granulosa cells were retrieved. Thereafter,  
335 flushing fluid was filtered through a 70-µm cell strainer, and concentrated granulosa cells were  
336 washed out from the strainer with PBS into a petri dish and transferred into light safe black  
337 Eppendorf tubes. After centrifugation (800 g for 10 min) at 4°C, the supernatant was discarded,  
338 and the pelleted granulosa cells were kept at 4°C until fluorescence imaging.

339

#### 340 **Fluorescence microscopic imaging**

341 All samples were imaged within a week post-collection.

342

343 ***IVIS imaging.*** Equine FF, granulosa cells, and FWB samples, as well as cultured porcine  
344 follicles, were collected and subjected to non-invasive and real-time fluorescence imaging using  
345 the IVIS imaging system (PerkinElmer; Waltham, Massachusetts, USA).

346

347 ***Fluorescence imaging.*** Following IVIS imaging, porcine follicles and equine FWB samples  
348 were fixed in 10% formalin solution for standard histology processing, generating 4–6 µm  
349 sample sections per slide. Fixed equine granulosa cells were spread on histology slides, air-dried,

350 immersed with a DAPI-contained mounting medium, and covered by a cover-slip. Slides were  
351 imaged with an epifluorescence microscope (EVOS FL-Auto Cell Imaging System, Thermo  
352 Fisher Scientific Inc., Waltham, MA, USA) or a confocal laser scanning with an Inverted  
353 microscope (Axiovert 200M) coupled with Zeiss ZEN digital imaging software (Carl Zeiss AG;  
354 Oberkochen, Germany).

355

### 356 **Statistical analyses**

357 All statistical analyses were performed using SPSS v22 software. The Student's t-test and One-  
358 way Analysis of Variance (ANOVA) were used, wherever appropriate, to compare the difference  
359 between groups (control, small and large follicles). The threshold of significance was set for p-  
360 values less or equal to 0.05. All data are expressed as mean  $\pm$  SEM.

361

### 362 **List of abbreviations**

363 PBS: Phosphate-buffered saline; FWB: Follicle Wall Biopsy; DAPI: 4',6-diamidino-2-  
364 phenylindole; GC: Granulosa Cells; FF: Follicular Fluid; IVIS: In Vivo Imaging System; DiI:  
365 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate; SPSS: Statistical Product  
366 and Service Solutions.

367

### 368 **Ethics approval and consent to participate**

369 All experimental procedures were performed according to the United States Government  
370 Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research and  
371 Training ([grants.nih.gov/grants/olaw/references/phspol.htm](https://grants.nih.gov/grants/olaw/references/phspol.htm)). The use of animals and procedures

372 were approved by the Institutional Animal Care and Use Committee of Southern Illinois  
373 University.

374

#### 375 **Consent for publication**

376 Not applicable.

377

#### 378 **Availability of data and materials**

379 Data sharing is not applicable to this article as no datasets were generated or analyzed during the  
380 current study.

381

#### 382 **Competing interests**

383 The authors declare that they have no competing interests.

384

#### 385 **Funding**

386 This material is based upon work that is supported by the National Institute of Food and  
387 Agriculture, U.S. Department of Agriculture, Hatch project accession number 1016077 and  
388 Multistate number W4171. Additional funds for research and APC were provided by the USDA-  
389 ARS Biophotonics (58-6402-3-018).

390

#### 391 **Authors' contributions**

392 JMF and ELG conceptualized the study; ME and RDA synthesized and characterized the  
393 liposome nanoparticles; JMF, GMI, and ELG performed the experiments and collected data;

394 JMF, GMI, ME, and ELG analyzed the data and wrote the first draft of the manuscript; RDA,  
 395 PLR and STW contributed to the conceptualization and data interpretation. All authors read and  
 396 approved the final manuscript.

397

### 398 **Acknowledgments**

399 The authors thank Dr. Melba Gastal and Gabriel Dutra for their technical assistance.

400

401

402

### 403 **References**

404

- 405 1. Motlik J, Crozet N, Fulka J: **Meiotic competence in vitro of pig oocytes isolated from early**  
 406 **antral follicles.** *Reproduction* 1984, **72**:323-328.
- 407 2. Gilchrist RB, Thompson JG: **Oocyte maturation: emerging concepts and technologies to**  
 408 **improve developmental potential in vitro.** *Theriogenology* 2007, **67**:6-15.
- 409 3. Feugang JM, Camargo-Rodríguez O, Memili E: **Culture systems for bovine embryos.** *Livestock*  
 410 *Science* 2009, **121**:141-149.
- 411 4. Gastal EL, Kot K, Ginther OJ: **Ultrasound-guided intrafollicular treatment in mares.**  
 412 *Theriogenology* 1995, **44**:1027-1037.
- 413 5. Bashir S, Gastal MO, Tazawa SP, Tarso S, Hales DB, Cuervo-Arango J, Baerwald AR, Gastal EL: **The**  
 414 **mare as a model for luteinized unruptured follicle syndrome: intrafollicular endocrine milieu.**  
 415 *Reproduction* 2016, **151**:271-283.
- 416 6. Hinrichs K: **Production of embryos by assisted reproduction in the horse.** *Theriogenology* 1998,  
 417 **49**:13-21.
- 418 7. Lonergan P, Fair T: **Maturation of Oocytes in Vitro.** *Annual Review of Animal Biosciences* 2016,  
 419 **4**:255-268.
- 420 8. Hansen PJ: **Implications of Assisted Reproductive Technologies for Pregnancy Outcomes in**  
 421 **Mammals.** *Annual Review of Animal Biosciences* 2020, **8**:395-413.
- 422 9. Horcajadas JA, Mínguez P, Dopazo J, Esteban FJ, Domínguez F, Giudice LC, Pellicer A, Simon C:  
 423 **Controlled ovarian stimulation induces a functional genomic delay of the endometrium with**  
 424 **potential clinical implications.** *The Journal of Clinical Endocrinology & Metabolism* 2008,  
 425 **93**:4500-4510.

- 426 10. Haouzi D, Assou S, Dechanet C, Anahory T, Dechaud H, De Vos J, Hamamah S: **Controlled**  
 427 **ovarian hyperstimulation for in vitro fertilization alters endometrial receptivity in humans:**  
 428 **protocol effects.** *Biology of reproduction* 2010, **82**:679-686.
- 429 11. Lu C-L, Yan Z-Q, Song X-L, Xu Y-Y, Zheng X-Y, Li R, Liu P, Feng H-L, Qiao J: **Effect of exogenous**  
 430 **gonadotropin on the transcriptome of human granulosa cells and follicular fluid hormone**  
 431 **profiles.** *Reproductive Biology and Endocrinology* 2019, **17**:49.
- 432 12. Sharma V, Whitehead M, Mason B, Pryse-Davies J, Ryder T, Dowsett M, Campbell S, Collins W:  
 433 **Influence of superovulation on endometrial and embryonic development.** *Fertility and Sterility*  
 434 1990, **53**:822-829.
- 435 13. Kot K, Gibbons J, Ginther O: **A technique for intrafollicular injection in cattle: effects of hCG.**  
 436 *Theriogenology* 1995, **44**:41-50.
- 437 14. da Silveira JC, Veeramachaneni DR, Winger QA, Carnevale EM, Bouma GJ: **Cell-secreted vesicles**  
 438 **in equine ovarian follicular fluid contain miRNAs and proteins: a possible new form of cell**  
 439 **communication within the ovarian follicle.** *Biology of reproduction* 2012, **86**:71, 71-10.
- 440 15. Sang Q, Yao Z, Wang H, Feng R, Wang H, Zhao X, Xing Q, Jin L, He L, Wu L: **Identification of**  
 441 **microRNAs in human follicular fluid: characterization of microRNAs that govern**  
 442 **steroidogenesis in vitro and are associated with polycystic ovary syndrome in vivo.** *The Journal*  
 443 *of Clinical Endocrinology & Metabolism* 2013, **98**:3068-3079.
- 444 16. Hailay T, Hoelker M, Poirier M, Gebremedhn S, Rings F, Saeed-Zidane M, Salilew-Wondim D,  
 445 Dauben C, Tholen E, Neuhooff C: **Extracellular vesicle-coupled miRNA profiles in follicular fluid**  
 446 **of cows with divergent post-calving metabolic status.** *Scientific reports* 2019, **9**:1-14.
- 447 17. Di Pietro C: **Exosome-mediated communication in the ovarian follicle.** *Journal of assisted*  
 448 *reproduction and genetics* 2016, **33**:303-311.
- 449 18. Tesfaye D, Hailay T, Salilew-Wondim D, Hoelker M, Bitseha S, Gebremedhn S: **Extracellular**  
 450 **vesicle mediated molecular signaling in ovarian follicle: Implication for oocyte developmental**  
 451 **competence.** *Theriogenology* 2020.
- 452 19. Dumesic DA, Meldrum DR, Katz-Jaffe MG, Krisher RL, Schoolcraft WB: **Oocyte environment:**  
 453 **follicular fluid and cumulus cells are critical for oocyte health.** *Fertility and sterility* 2015,  
 454 **103**:303-316.
- 455 20. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Woo Joo S, Zarghami N, Hanifehpour Y, Samiei M,  
 456 Kouhi M, Nejati-Koshki K: **Liposome: Classification, preparation, and Applications.** *Nanoscale*  
 457 *Research Letters* 2013, **8**:102.
- 458 21. Grijalva M, Vallejo-López MJ, Salazar L, Camacho J, Kumar B: **Cytotoxic and antiproliferative**  
 459 **effects of nanomaterials on cancer cell lines: a review.** *Unraveling the Safety Profile of*  
 460 *Nanoscale Particles and Materials: From Biomedical to Environmental Applications* 2018:63.
- 461 22. Feugang JM, Rhoads CE, Mustapha PA, Tardif S, Parrish JJ, Willard ST, Ryan PL: **Treatment of**  
 462 **boar sperm with nanoparticles for improved fertility.** *Theriogenology* 2019, **137**:75-81.
- 463 23. Ferrazza RdA, Garcia HDM, Schmidt EMdS, Mihm Carmichael M, Souza FFd, Burchmore R, Sartori  
 464 R, Eckersall PD, Ferreira JCP: **Quantitative proteomic profiling of bovine follicular fluid during**  
 465 **follicle development.** *Biology of reproduction* 2017, **97**:835-849.
- 466 24. Fahiminiya S, Labas V, Roche S, Dacheux J-L, Gérard N: **Proteomic analysis of mare follicular**  
 467 **fluid during late follicle development.** *Proteome science* 2011, **9**:54.
- 468 25. Dutra G, Ishak G, Pechanova O, Pechan T, Peterson D, Jacob J, Willard S, Ryan P, Gastal E,  
 469 Feugang J: **Seasonal variation in equine follicular fluid proteome.** *Reproductive Biology and*  
 470 *Endocrinology* 2019, **17**:29.

- 471 26. Paes VM, Liao SF, Figueiredo JR, Willard ST, Ryan PL, Feugang JM: **Proteome changes of porcine**  
 472 **follicular fluid during follicle development.** *Journal of animal science and biotechnology* 2019,  
 473 **10:94.**
- 474 27. Walter J, Huwiler F, Fortes C, Grossmann J, Roschitzki B, Hu J, Naegeli H, Laczko E, Bleul U:  
 475 **Analysis of the equine “cumulome” reveals major metabolic aberrations after maturation in**  
 476 **vitro.** *BMC genomics* 2019, **20:588.**
- 477 28. Ishak GM, Dutra GA, Gastal GD, Gastal MO, Feugang JM, Gastal EL: **Transition to the ovulatory**  
 478 **season in mares: An investigation of antral follicle receptor gene expression in vivo.** *Molecular*  
 479 *Reproduction and Development* 2019, **86:1832-1845.**
- 480 29. Ishak G, Bashir S, Dutra G, Gastal G, Gastal M, Cavinder C, Feugang J, Gastal E: **In vivo antral**  
 481 **follicle wall biopsy: a new research technique to study ovarian function at the cellular and**  
 482 **molecular levels.** *Reproductive Biology and Endocrinology* 2018, **16:71.**
- 483 30. Wang Q, He L, Fan D, Liang W, Fang J: **Improving the anti-inflammatory efficacy of**  
 484 **dexamethasone in the treatment of rheumatoid arthritis with polymerized stealth liposomes**  
 485 **as a delivery vehicle.** *Journal of Materials Chemistry B* 2020, **8:1841-1851.**
- 486 31. Ren H, He Y, Liang J, Cheng Z, Zhang M, Zhu Y, Hong C, Qin J, Xu X, Wang J: **Role of Liposome**  
 487 **Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy.** *ACS Applied*  
 488 *Materials & Interfaces* 2019, **11:20304-20315.**
- 489 32. Feugang JM, Youngblood RC, Greene JM, Willard ST, Ryan PL: **Self-illuminating quantum dots**  
 490 **for non-invasive bioluminescence imaging of mammalian gametes.** *Journal of*  
 491 *nanobiotechnology* 2015, **13:38.**
- 492 33. Ginther OJ, Siddiqui MAR, Beg MA: **Progesterone responses to intravenous and intrauterine**  
 493 **infusions of prostaglandin F2 in mares.** *Reproduction, Fertility and Development* 2009, **21:688-**  
 494 **695.**
- 495 34. Weber J, Causey R, Emmans E: **Induction of luteolysis in mares by ultrasound-guided**  
 496 **intraluteal treatment with PGF2alpha.** *Theriogenology* 2001, **55:1769-1776.**
- 497 35. Ginther O, Gastal E, Gastal M, Bergfelt D, Baerwald A, Pierson R: **Comparative study of the**  
 498 **dynamics of follicular waves in mares and women.** *Biology of reproduction* 2004, **71:1195-1201.**
- 499 36. Jha RK, Jha PK, Chaudhury K, Rana SVS, Guha SK: **An emerging interface between life science**  
 500 **and nanotechnology: present status and prospects of reproductive healthcare aided by nano-**  
 501 **biotechnology.** *Nano Reviews* 2014, **5:10.3402/nano.v3405.22762.**
- 502 37. Yáñez-Mó M, Siljander PR-M, Andreu Z, Bedina Zavec A, Borràs FE, Buzas EI, Buzas K, Casal E,  
 503 Cappello F, Carvalho J: **Biological properties of extracellular vesicles and their physiological**  
 504 **functions.** *Journal of extracellular vesicles* 2015, **4:27066.**
- 505 38. Stathopoulos G, Boulikas T: **Lipoplatin formulation review article.** *Journal of drug delivery* 2012,  
 506 **2012.**
- 507 39. Carnevale E: **The mare model for follicular maturation and reproductive aging in the woman.**  
 508 *Theriogenology* 2008, **69:23-30.**
- 509 40. Bashir ST, Baerwald AR, Gastal MO, Pierson RA, Gastal EL: **Follicle growth and endocrine**  
 510 **dynamics in women with spontaneous luteinized unruptured follicles versus ovulation.** *Human*  
 511 *Reproduction* 2018, **33:1130-1140.**
- 512 41. Quach N, Mock J, Scholpa N, Eggert M, Payre C, Lambeau G, Arnold R, Cummings B: **Role of the**  
 513 **phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.** *Molecular*  
 514 *pharmaceutics* 2014, **11:3443-3451.**

- 515 42. Kamps JA, Morselt HW, Swart PJ, Meijer DK, Scherphof GL: **Massive targeting of liposomes,**  
516 **surface-modified with anionized albumins, to hepatic endothelial cells.** *Proceedings of the*  
517 *National Academy of Sciences* 1997, **94**:11681-11685.
- 518 43. Bartlett GR: **Phosphorus assay in column chromatography.** *Journal of Biological Chemistry* 1959,  
519 **234**:466-468.
- 520 44. Gastal E, Gastal M, Wiltbank M, Ginther O: **Follicle deviation and intrafollicular and systemic**  
521 **estradiol concentrations in mares.** *Biology of reproduction* 1999, **61**:31-39.  
522

523

524

525

526 **Figure legends**

527

528 **Figure 1.** Liposome characterization through Malvern Zetasizer Nano ZS.

529 The Z-average diameter (**A**) and Zeta potential (**B**) parameters were measured in 3 replicates  
530 (dilutions 1, 2, and 3). The insert is a TEM micrograph of liposome nanoparticles in monomer  
531 (arrows) and aggregate formations.

532

533 **Figure 2.** Fluorescence imaging of liposome formulations using In Vivo Imaging System (IVIS).

534 Fluorescence imaging (480 nm excitation/570 nm emission) of 3 stock solutions (an average of  
535  $1.9 \times 10^{11} \pm 8. \times 10^9$  radiance efficiency; **A**) and the working solution (**B**) are shown. The blue box  
536 surrounding the right panel (**B**) has a Phosphate-Buffered Saline solution (PBS) solution and  
537 diluted liposome solution (23.1  $\mu$ M; an average of  $6.5 \times 10^{10} \pm 8. \times 10^9$  radiance).

538

539 **Figure 3.** Fluorescence imaging of *in vitro* culture porcine follicles.

540 The micrograph (**A**) corresponds to fluorescence detected with In Vivo Imaging System (IVIS)  
541 of pig follicles microinjected with 5  $\mu$ l of Phosphate-Buffered Saline solution (PBS; upper  
542 series), fluorescence liposomes (4.6 nmoles/follicle; middle series), and liposomal encapsulated  
543 doxorubicin (10  $\mu$ g/follicle; lower series) and cultured 24 h before imaging. All fluorescence  
544 quantifications are shown in (**B**).

545

546 **Figure 4.** *In situ* fluorescence imaging of microinjected porcine follicles.

547 Following microinjection and 24 h culture of porcine follicles, follicles were fixed and subjected  
548 to standard histology processing. Representative micrographs with sections of antral follicle  
549 walls/layers injected with PBS (**A**, autofluorescence) or fluorescent liposomes (**B**, green color)  
550 are shown. The green fluorescence is mainly located on the cell plasma membrane.

551 Representative micrographs with sections of antral follicles injected with non-fluorescent  
552 liposomes loaded with doxorubicin are mainly located in the nuclei of follicle wall cells (**C**, **D**),  
553 which colocalization with DAPI (blue) is highlighted with the insert in Micrograph D,  
554 corresponding to fluorescence overlaid with visible light. Granulosa cells (GC), Theca interna  
555 (TI), and Theca externa (TE) constitute the cell layers of the ovarian follicle wall.

556

557 **Figure 5.** Representative fluorescence imaging of equine follicle wall biopsies (FWB).

558 Biopsies were obtained from *in vivo* microinjected small (SF: n = 6) and large (LF: n = 5)  
559 follicles. In parallel, FWB samples were harvested from Phosphate-Buffered Saline solution  
560 (PBS)-injected follicles to serve as Control with a subset being *in vitro* labeled with comparable  
561 fluorescence liposome concentrations. All FWB samples were imaged with the In Vivo Imaging  
562 System (IVIS) and data (Radiant Efficiency) were quantified (mean  $\pm$  sem). Letters indicate  
563 significant differences (a, b, c;  $P < 10^{-4}$ ). N = total number of samples analyzed.

564  
565 **Figure 6.** Representative fluorescence imaging of equine follicular fluid (FF) following *in vivo*  
566 labeling with fluorescence liposome nanoparticles.  
567 The In Vivo Imaging System (IVIS) of FF collected from small and large follicles microinjected  
568 with fluorescent liposomes is shown in **A** and **B**, respectively. The quantification of collected  
569 fluorescence signals is plotted minus the values of FF originated from Phosphate-Buffered Saline  
570 solution (PBS)-microinjected follicles that were considered as the background noise.  
571 Fluorescence signal (Radiant Efficiency) data are mean ( $\pm$  SEM) and letters indicate a significant  
572 difference (a, b;  $P < 10^{-4}$ ). N = total number of samples analyzed.

573  
574 **Figure 7.** Representative fluorescence imaging of *in vivo* labeled equine granulosa cells (GC).  
575 The micrograph (left panel) shows tubes containing GC collected from follicles injected with  
576 Phosphate-Buffered Saline solution (PBS) to serve as Control, and liposome-microinjected  
577 follicles (**A**). Mean ( $\pm$  SEM) fluorescence data (Radiant Efficiency) of small (SF) and large (LF)  
578 follicles are indicated (**B**). Letters denote significant differences (a, b, c;  $P < P < 10^{-5}$ ). N = total  
579 number of samples analyzed.

580  
581 **Figure 8.** *In vivo* fluorescence imaging of liposome binding to equine ovarian antral follicles.  
582 Micrograph **A** showed a fragment of the follicle wall biopsy (FWB) of an antral follicle injected  
583 with Phosphate-Buffered Saline solution (PBS). A representative sample of FWB harvested from  
584 antral follicles injected with fluorescent liposomes are shown in Micrograph **B**. Granulosa cells  
585 flushed from liposome injected antral follicles are shown in Micrographs **C and D**. The green  
586 fluorescence detection of liposome was detected in the mural granulosa cells layers and the  
587 major signal was located in the cells' plasma membrane (Insert in micrograph **B**), which is also  
588 confirmed in Micrographs **C and D**. Nuclei are counterstained in blue with DAPI.  
589

# Figures




Figure 1

Liposome characterization through Malvern Zetasizer Nano ZS. The Z-average diameter (A) and Zeta potential (B) parameters were measured in 3 replicates (dilutions 1, 2, and 3). The insert is a TEM micrograph of liposome nanoparticles in monomer (arrows) and aggregate formations.






Figure 2

Fluorescence imaging of liposome formulations using In Vivo Imaging System (IVIS). Fluorescence imaging (480 nm excitation/570 nm emission) of 3 stock solutions (an average of  $1.9 \times 10^{11} \pm 8. \times 10^9$  radiance efficiency; A) and the working solution (B) are shown. The blue box surrounding the right panel (B) has a Phosphate-Buffered Saline solution (PBS) solution and diluted liposome solution ( $23.1 \mu\text{M}$ ; an average of  $6.5 \times 10^{10} \pm 8. \times 10^9$  radiance).




**Figure 3**

Fluorescence imaging of in vitro culture porcine follicles. The micrograph (A) corresponds to fluorescence detected with In Vivo Imaging System (IVIS) of pig follicles microinjected with  $5 \mu\text{l}$  of Phosphate-Buffered Saline solution (PBS; upper series), fluorescence liposomes ( $4.6 \text{ nmoles/follicle}$ ; middle series), and liposomal encapsulated doxorubicin ( $10 \mu\text{g/follicle}$ ; lower series) and cultured 24 h before imaging. All fluorescence quantifications are shown in (B).




**Figure 4**

In situ fluorescence imaging of microinjected porcine follicles. Following microinjection and 24 h culture of porcine follicles, follicles were fixed and subjected to standard histology processing. Representative micrographs with sections of antral follicle walls/layers injected with PBS (A, autofluorescence) or fluorescent liposomes (B, green color) are shown. The green fluorescence is mainly located on the cell plasma membrane. Representative micrographs with sections of antral follicles injected with non-fluorescent liposomes loaded with doxorubicin are mainly located in the nuclei of follicle wall cells (C, D), which colocalization with DAPI (blue) is highlighted with the insert in Micrograph D, corresponding to fluorescence overlaid with visible light. Granulosa cells (GC), Theca interna (TI), and Theca externa (TE) constitute the cell layers of the ovarian follicle wall.




**Figure 5**

Representative fluorescence imaging of equine follicle wall biopsies (FWB). Biopsies were obtained from in vivo microinjected small (SF: n = 6) and large (LF: n = 5) follicles. In parallel, FWB samples were harvested from Phosphate-Buffered Saline solution (PBS)-injected follicles to serve as Control with a subset being in vitro labeled with comparable fluorescence liposome concentrations. All FWB samples were imaged with the In Vivo Imaging System (IVIS) and data (Radiant Efficiency) were quantified (mean  $\pm$  sem). Letters indicate significant differences (a, b, c;  $P < 10^{-4}$ ). N = total number of samples analyzed.




**Figure 6**

Representative fluorescence imaging of equine follicular fluid (FF) following in vivo labeling with fluorescence liposome nanoparticles. The In Vivo Imaging System (IVIS) of FF collected from small and large follicles microinjected with fluorescent liposomes is shown in A and B, respectively. The quantification of collected fluorescence signals is plotted minus the values of FF originated from Phosphate-Buffered Saline solution (PBS)-microinjected follicles that were considered as the background noise. Fluorescence signal (Radiant Efficiency) data are mean ( $\pm$  SEM) and letters indicate a significant difference (a, b;  $P < 10^{-4}$ ). N = total number of samples analyzed.



**Figure 7**

Representative fluorescence imaging of in vivo labeled equine granulosa cells (GC). The micrograph (left panel) shows tubes containing GC collected from follicles injected with Phosphate-Buffered Saline solution (PBS) to serve as Control, and liposome-microinjected follicles (A). Mean ( $\pm$  SEM) fluorescence data (Radiant Efficiency) of small (SF) and large (LF) follicles are indicated (B). Letters denote significant differences (a, b, c;  $P < 10^{-5}$ ). N = total number of samples analyzed.



**Figure 8**

In vivo fluorescence imaging of liposome binding to equine ovarian antral follicles. Micrograph A showed a fragment of the follicle wall biopsy (FWB) of an antral follicle injected with Phosphate-Buffered Saline solution (PBS). A representative sample of FWB harvested from antral follicles injected with fluorescent liposomes are shown in Micrograph B. Granulosa cells flushed from liposome injected antral follicles are shown in Micrographs C and D. The green fluorescence detection of liposome was detected in the mural granulosa cells layers and the major signal was located in the cells' plasma membrane (Insert in micrograph B), which is also confirmed in Micrographs C and D. Nuclei are counterstained in blue with DAPI.